You are here

AveXis

Novartis Is Looking for Deals. Are These 3 Biotechs on Its List?

Motley Fool

Mon, 05/2/22 - 11:57 am

The Medicines Company

Novartis reshuffling doesn't portend a pullback from gene therapy, company says

Fierce Pharma

Wed, 09/22/21 - 11:56 am

Former AveXis executives launch gene therapy startup with uncommon targets

BioPharma Dive

Thu, 02/25/21 - 09:34 am

Jaguar Gene Therapy

Big gene therapy names line up behind experimental Covid-19 vaccine

Stat

Thu, 05/28/20 - 10:44 am

Taysha Launches With $30M to Bring Gene Therapy to CNS Disorders

Xconomy

Wed, 04/29/20 - 10:47 am

No sanctions for Novartis as FDA ends review of gene therapy violations

BioSpace

Tue, 03/31/20 - 11:14 am

data manipulation

Novartis' David Lennon on next steps for AveXis, selling Zolgensma's price to the public

BioPharma Dive

Wed, 01/15/20 - 11:36 pm

Zolgensma hits the ground running, says Novartis

Pharmaforum

Tue, 10/22/19 - 10:33 am

Novartis to put AveXis into protective custody after data manipulation scandal

Fierce Pharma

Tue, 09/24/19 - 10:17 pm

Novartis earlier acknowledged Zolgensma data errors to FDA but blamed them on poor reporting

Fierce Pharma

Tue, 08/27/19 - 12:06 pm

FDA asks why Novartis took two months to launch formal internal probe, after AveXis flagged data manipulation

Endpoints

Fri, 08/23/19 - 10:17 am

AveXis scientific founder fires back at Novartis CEO Vas Narasimhan, 'categorically denies any wrongdoing'

Endpoints

Mon, 08/19/19 - 11:36 pm

Warning signs were always there for Novartis’s Avexis deal

EP Vantage

Fri, 08/16/19 - 10:01 am

AveXis scientific founder is out as Novartis names a new CSO in wake of an ethics scandal

Endpoints

Wed, 08/14/19 - 11:15 am

Novartis used manipulated data in winning Zolgensma approval, FDA says

Biopharma Dive

Wed, 08/7/19 - 10:57 am

spinal muscular atrophy

New Zolgensma data suggest comparable efficacy to Spinraza — analysts

Endpoints

Mon, 05/6/19 - 09:52 pm

spinal muscular atrophy

Ionis slides after AveXis reports SMA data for Zolgensma

BioCentury

Wed, 04/17/19 - 10:41 pm

Ionis Pharmaceuticals

lcinical trials

spinal muscular atrophy

Novartis CEO Vas Narasimhan On The Price Of Gene Therapies: 'It's A Challenge We Have To Solve'

Forbes

Thu, 11/29/18 - 11:11 am

3 Best Biotech Acquisitions of 2018 (So Far)

Motley Fool

Thu, 07/5/18 - 09:57 am

Juno Therapeutics

Foundation Medicine

Novartis' brand-new gene therapy player AveXis will build $55M plant, hire 200

Fierce Pharma

Wed, 05/23/18 - 03:03 pm

drug manufacturing

Pages